mb glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Microdosed GLP-1 (Semaglutide)
Description
The STEP-HFpEF DM trial investigated whether the changes in glucose levels in HFpEF patients with obesity moderates the treatment benefits of GLP-1 RAs
But in a handful of cases, including weight loss medications, states get to decide for themselves
Also, LBM reduction was often assessed using BIA or DXA, both of which have limitations in distinguishing between muscle, organ mass, and extracellular fluid
doi: 10.3390/nu7020730
3f) despite their structural similarity to JWU-A021
